OPC 14117

Drug Profile

OPC 14117

Latest Information Update: 19 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Indans; Neuroprotectants; Piperazines
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebral ischaemia; CNS trauma; Cognition disorders; Huntington's disease; Parkinson's disease

Most Recent Events

  • 09 Jan 2001 No-Development-Reported for Cerebral ischaemia in USA (Unknown route)
  • 09 Jan 2001 No-Development-Reported for CNS trauma in USA (Unknown route)
  • 09 Jan 2001 No-Development-Reported for Cognition disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top